NCT04546945 Aberrant Expression of CD56 in Patients With Hematologic Malignancies.
| NCT ID | NCT04546945 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Asmaa Hassan mohamed Abdel Mawjoud |
| Condition | Hematologic Malignancies |
| Study Type | OBSERVATIONAL |
| Enrollment | 38 participants |
| Start Date | 2027-03-20 |
| Primary Completion | 2027-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 38 participants in total. It began in 2027-03-20 with a primary completion date of 2027-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
CD56(cluster of differentiation 56) was found to be ectopically expressed in multiple myeloma . A met analysis indicated that CD56 over expression may be an adverse prognostic factor in AML. To the best of our knowledge, no available data the expression pattern of CD56 in other Hematologic malignancies. This work is designed to evaluate the expression pattern of CD56 in hematologic malignancies.
Eligibility Criteria
Inclusion Criteria: * Patients with hematologic malignancies. * Newly diagnosed Exclusion Criteria: * Patients with hematologic disorders other than hematologic malignancies.
Contact & Investigator
Maged S Mahmoud, prof
STUDY DIRECTOR
Assiut University
Frequently Asked Questions
Who can join the NCT04546945 clinical trial?
This trial is open to participants of all sexes, studying Hematologic Malignancies. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04546945 currently recruiting?
Yes, NCT04546945 is actively recruiting participants. Contact the research team at a94asmaa@gmail.com for enrollment information.
Where is the NCT04546945 trial being conducted?
This trial is being conducted at Asyut, Egypt, Asyut, Egypt.
Who is sponsoring the NCT04546945 clinical trial?
NCT04546945 is sponsored by Asmaa Hassan mohamed Abdel Mawjoud. The principal investigator is Maged S Mahmoud, prof at Assiut University. The trial plans to enroll 38 participants.